ERBB2 and head and neck squamous cell carcinoma: AC480, a novel EGFR and HER2 inhibitor, administered before and during exposure to gamma radiation, was discovered to enhance the radiosensitivity of HNSCC cells and significantly reduce tumor size in vivo (59).